Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences (SGHT) reported Q3 2025 results with revenue of $19.9 million, slightly lower than $20.2 million a year ago, as Surgical Glaucoma held steady and Dry Eye remained soft. Gross profit was $17.2 million while operating expenses fell to $25.1 million, narrowing the net loss to $8.2 million from $11.1 million. For the nine months, revenue was $57.0 million and net loss was $34.3 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, down from $120.4 million at year-end, reflecting operating cash outflows. Long-term debt stood at $40.1 million. The company amended its Hercules loan in September, extending the interest-only period to February 1, 2027 and increasing potential incremental tranches (subject to lender approval) while maintaining the $65 million facility.
Management executed a targeted restructuring in Q3, recording $2.8 million of charges to reduce operating expenses. Subsequent to quarter-end, two Medicare Administrative Contractors set jurisdiction-wide pricing for CPT 0563T tied to TearCare, effective retroactive to January 1, 2025. A prior $34 million jury verdict in patent litigation awaits judgment and may be affected by USPTO reexaminations.
Sight Sciences (SGHT) reported Q3 2025 results with revenue of $19.9 million, slightly lower than $20.2 million a year ago, as Surgical Glaucoma held steady and Dry Eye remained soft. Gross profit was $17.2 million while operating expenses fell to $25.1 million, narrowing the net loss to $8.2 million from $11.1 million. For the nine months, revenue was $57.0 million and net loss was $34.3 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, down from $120.4 million at year-end, reflecting operating cash outflows. Long-term debt stood at $40.1 million. The company amended its Hercules loan in September, extending the interest-only period to February 1, 2027 and increasing potential incremental tranches (subject to lender approval) while maintaining the $65 million facility.
Management executed a targeted restructuring in Q3, recording $2.8 million of charges to reduce operating expenses. Subsequent to quarter-end, two Medicare Administrative Contractors set jurisdiction-wide pricing for CPT 0563T tied to TearCare, effective retroactive to January 1, 2025. A prior $34 million jury verdict in patent litigation awaits judgment and may be affected by USPTO reexaminations.
Sight Sciences (SGHT) reported leadership changes and furnished Q3 updates. The company promoted Alison Bauerlein to Chief Operating Officer, effective November 5, 2025; she will serve as Principal Operating Officer and cease serving as CFO, Treasurer, Principal Financial Officer and Principal Accounting Officer.
James (Jim) Rodberg was promoted to Chief Financial Officer and Treasurer, also effective November 5, 2025, and will serve as Principal Financial and Accounting Officer. Bauerlein’s compensation includes a $485,000 base salary, a cash bonus target at 65% of salary, and RSUs valued at $150,000 vesting in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Rodberg’s terms include a $400,000 base salary, a 50% bonus target, and $100,000 in RSUs with the same vesting schedule.
Brenda Becker and Erica Rogers resigned from the Board effective November 4, 2025, stating no disagreement with the company. The Board size was reduced from nine to seven, and Catherine Mazzacco was reassigned to Class I with a term ending at the 2028 annual meeting. The company furnished an earnings press release and a leadership press release, and posted an investor presentation.
Sight Sciences (SGHT) reported leadership changes and furnished Q3 updates. The company promoted Alison Bauerlein to Chief Operating Officer, effective November 5, 2025; she will serve as Principal Operating Officer and cease serving as CFO, Treasurer, Principal Financial Officer and Principal Accounting Officer.
James (Jim) Rodberg was promoted to Chief Financial Officer and Treasurer, also effective November 5, 2025, and will serve as Principal Financial and Accounting Officer. Bauerlein’s compensation includes a $485,000 base salary, a cash bonus target at 65% of salary, and RSUs valued at $150,000 vesting in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Rodberg’s terms include a $400,000 base salary, a 50% bonus target, and $100,000 in RSUs with the same vesting schedule.
Brenda Becker and Erica Rogers resigned from the Board effective November 4, 2025, stating no disagreement with the company. The Board size was reduced from nine to seven, and Catherine Mazzacco was reassigned to Class I with a term ending at the 2028 annual meeting. The company furnished an earnings press release and a leadership press release, and posted an investor presentation.
Sight Sciences announced that two Medicare Administrative Contractors, Novitas and FCSO, established jurisdiction-wide pricing for CPT 0563T, which describes the TearCare procedure. The Medicare fee schedule amount is $1,141.59, effective for dates of service on and after January 1, 2025, across all Novitas and FCSO jurisdictions.
The local fee schedules are active for claim processing and are expected to be posted on the Novitas and FCSO websites. TearCare claims in these areas will be payable based on individual medical necessity determinations. The regions covered by these MACs have an estimated 10.4 million total covered lives. The company also posted an investor presentation and plans to provide updated revenue and adjusted operating expenses guidance during its third quarter 2025 earnings call.
Sight Sciences, Inc. reporting person Brenton Taylor disclosed a sale of 591 shares of common stock on 10/06/2025. The sale was executed to cover the reporting person's tax liability related to the vesting of restricted stock units and occurred in multiple transactions at prices ranging from $3.32 to $3.45, with a weighted average price of $3.37. After the reported sale, the reporting person beneficially owned 185,249 shares, held directly. The form bears a signature date of 10/08/2025.
Sight Sciences, Inc. filing a Form 144 reports a proposed sale of 591 common shares with an aggregate market value of $1,992.32. The seller acquired these shares on 09/30/2025 through restricted stock vesting and the payment type is listed as compensation. The proposed approximate sale date is 10/06/2025 on NASDAQ. The filing shows 52,367,359 shares outstanding for the issuer and indicates no sales by the seller in the past three months. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal notice language.
Sight Sciences (SGHT) disclosed an insider transaction by its Chief Financial Officer. On 10/02/2025, the officer reported a sale of 19,948 shares of common stock at $3.3 per share, coded “S.” Following the transaction, the officer directly holds 597,520 shares.
The filing notes the shares were sold to cover the reporting person’s tax liability associated with the vesting of restricted stock units. This reflects a routine tax-related disposition rather than a discretionary portfolio trade.
Sight Sciences (SGHT) President & CEO, Director, and 10% owner Paul Badawi reported a sale of common stock on 10/01/2025. He sold 24,441 shares at $3.34 per share (Code S), as noted in the filing’s footnote, to cover tax liabilities arising from the vesting of restricted stock units.
Following this transaction, Badawi beneficially owns 5,962,502 shares of Sight Sciences common stock directly. The filing indicates the disposition was related to tax withholding tied to equity compensation vesting.
David Badawi, Chief Technology Officer and director of Sight Sciences, Inc. (SGHT), reported a sale of 6,033 shares of common stock on 10/03/2025 at a price of $3.27 per share. The filing states the shares were sold to cover the reporting person's tax liability from the vesting of restricted stock units. After the sale, Mr. Badawi beneficially owned 1,864,992 shares of common stock.
This Form 144 for Sight Sciences, Inc. (SGHT) notifies a proposed sale of 9,731 common shares held at Fidelity Brokerage Services LLC with an aggregate market value of $31,848.59, with an approximate sale date of 10/03/2025. The shares were acquired on 09/30/2025 through restricted stock vesting and the acquisition payment is listed as compensation. The filing also discloses a prior sale by Jeremy Hayden of 9,160 common shares on 07/03/2025 for gross proceeds of $38,235.67. The filer represents, by signing, that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 filing: A shareholder filed a notice to sell up to 15,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 10/03/2025. The filing lists an aggregate market value of $49,276.20 for the proposed sale.
The shares were acquired via restricted stock vesting: 11,236 shares on 10/17/2024 and 3,764 shares on 10/18/2024, recorded as compensation. Shares outstanding were 52,367,359 at the time cited.
Recent activity over the past three months shows sales by Matthew Link of common stock: 10,000 shares for $35,227.21 on 09/12/2025; 15,990 shares for $55,291.81 on 09/16/2025; 20,000 shares for $73,400.00 on 09/19/2025; and 20,753 shares for $73,350.73 on 09/23/2025.